| Primary |
| Gout |
66.7% |
| Hypertension |
33.3% |
|
| Malaise |
66.7% |
| Stevens-johnson Syndrome |
33.3% |
|
| Secondary |
| Product Used For Unknown Indication |
20.2% |
| Drug Use For Unknown Indication |
19.1% |
| Atrial Fibrillation |
12.9% |
| Hypertension |
7.8% |
| Essential Hypertension |
5.5% |
| Cardiac Failure |
4.0% |
| Arrhythmia |
3.3% |
| Prophylaxis |
3.3% |
| Diabetes Mellitus |
2.9% |
| Urinary Tract Infection |
2.4% |
| Angina Pectoris |
2.2% |
| Depressive Symptom |
2.2% |
| Benign Prostatic Hyperplasia |
2.0% |
| Cardiomyopathy |
2.0% |
| Respiratory Tract Infection |
2.0% |
| Lung Infection |
1.8% |
| Micturition Disorder |
1.8% |
| Depression |
1.6% |
| Pulmonary Embolism |
1.6% |
| Type 2 Diabetes Mellitus |
1.6% |
|
| Renal Failure Acute |
22.0% |
| Renal Failure |
11.0% |
| Eczema |
7.7% |
| Hyperthyroidism |
7.7% |
| Overdose |
6.6% |
| Malaise |
4.4% |
| Persecutory Delusion |
4.4% |
| Transient Ischaemic Attack |
4.4% |
| Vomiting |
4.4% |
| Thyroid Neoplasm |
3.3% |
| Torsade De Pointes |
3.3% |
| Tricuspid Valve Incompetence |
3.3% |
| Cardioactive Drug Level Increased |
2.2% |
| Fall |
2.2% |
| Haemothorax |
2.2% |
| Leukopenia |
2.2% |
| Mitral Valve Incompetence |
2.2% |
| Pulmonary Fibrosis |
2.2% |
| Purpura |
2.2% |
| Therapeutic Agent Toxicity |
2.2% |
|
| Concomitant |
| Drug Use For Unknown Indication |
27.8% |
| Product Used For Unknown Indication |
14.3% |
| Atrial Fibrillation |
10.2% |
| Cardiac Failure |
7.2% |
| Hypertension |
6.3% |
| Prophylaxis |
3.6% |
| Thrombosis Prophylaxis |
3.4% |
| Atrial Flutter |
3.0% |
| Bone Marrow Failure |
2.9% |
| Pain |
2.5% |
| Arrhythmia |
2.3% |
| Anxiety |
2.2% |
| Depression |
2.2% |
| Lung Disorder |
2.2% |
| Bronchitis |
2.0% |
| Type 2 Diabetes Mellitus |
2.0% |
| Diabetes Mellitus |
1.6% |
| Epilepsy |
1.6% |
| Abnormal Behaviour |
1.4% |
| Cardiac Disorder |
1.4% |
|
| Renal Failure Acute |
12.9% |
| International Normalised Ratio Increased |
10.5% |
| Thrombocytopenia |
8.9% |
| Overdose |
7.3% |
| Hyponatraemia |
6.5% |
| Interstitial Lung Disease |
5.6% |
| Weight Decreased |
5.6% |
| Fall |
4.8% |
| Toxic Skin Eruption |
4.8% |
| Acute Generalised Exanthematous Pustulosis |
3.2% |
| General Physical Health Deterioration |
3.2% |
| Melaena |
3.2% |
| Pancreatitis Acute |
3.2% |
| Rectal Haemorrhage |
3.2% |
| Renal Impairment |
3.2% |
| Urinary Retention |
3.2% |
| Vomiting |
3.2% |
| Hypothermia |
2.4% |
| Lung Infection |
2.4% |
| Mesenteric Vein Thrombosis |
2.4% |
|
| Interacting |
| Drug Use For Unknown Indication |
28.6% |
| Product Used For Unknown Indication |
22.4% |
| Atrial Fibrillation |
12.2% |
| Arrhythmia |
10.2% |
| Atrial Flutter |
8.2% |
| Essential Hypertension |
4.1% |
| Hypertension |
4.1% |
| Prophylaxis |
4.1% |
| Angina Pectoris |
2.0% |
| Benign Prostatic Hyperplasia |
2.0% |
| Diabetes Mellitus |
2.0% |
|
| Overdose |
20.0% |
| Ventricular Extrasystoles |
20.0% |
| Fall |
10.0% |
| Pelvic Fracture |
10.0% |
| Renal Function Test Abnormal |
10.0% |
| Somnolence |
10.0% |
| Therapeutic Agent Toxicity |
10.0% |
| Traumatic Haematoma |
10.0% |
|
